Many hospitals are beginning to use remote readings via CGM to monitor blood glucose levels for Covid-19 patients with diabetes. Through the resulting reduced clinician contact, this is helping to curb virus transmission and to preserve scarce protective gear. The entire article can be found in the Wall Street Journal. By using CGM, manual finger-stick or blood draw methods performed by nurses in patients' rooms can be cut back dramatically.
This month, the FDA told DexCom and Abbott Laboratories that they could provide their remote continuous glucose monitors to hospitals to support care of Covid-19 patients. Previously, the companies didn’t ship them to hospitals because they weren’t FDA-approved for inpatient use, though doctors had discretion to allow patients who already had them to continue using them.